Cadrenal Therapeutics has partnered with Abbott for the TECH-LVAD trial to assess the safety and efficacy of tecarfarin in ...

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Collaboration Agreement with Abbott for Phase 3 TECH-LVAD Trial On March 4, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a ...

Advocate Children's Hospital formally launched its pediatric heart transplant program at the Oak Lawn hospital today, having ...

Australia's first implant of a BiVACOR Total Artificial Heart has been announced as an unmitigated clinical success, with the patient becoming the ...

The global IV therapy and vein access devices market is on a trajectory of significant growth, projected to expand from USD 28.7 billion in 2024 to an estimated USD 47.3 billion by 2034. With a ...

The two major players in the Greater New Orleans health care industry – Ochsner Health and LCMC Health – continue to increase ...

John A. McCoy Jr., Vice President at Abbott Laboratories, sold 562 shares for $77,651 at an average price of $138.17 per ...

In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...

Vail Scientific's VSNO sepsis screening device is a noninvasive, handheld breath test that measures exhaled nitric oxide for ...

C Medical Technologies announced today that it closed a Series D financing round resulting in gross proceeds of up to $175 ...